title: Induction of complete remission in a patient with acute myeloid leukemia refractory to high-dose chemotherapy through treatment with 5-azacytidine.
abstract: For patients with acute myeloid leukemia refractory to intensive chemotherapy prognosis is very poor and treatment options are limited. 5-Azacytidine, a demethylating drug, is effective in the treatment of myelodysplastic syndromes when administered at a low-dose, subcutaneously. We report a case of a patient with AML refractory to induction chemotherapy as well as to two high-dose salvage regimens. The patient achieved CR through monotherapy with low-dose azacytidine.
authors.affiliation: Department of Hematology, Oncology, Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, D-40225 Düsseldorf, Germany. kuendgen@med.uni-duesseldorf.de
authors.forename: A
authors.initials: A
authors.lastname: Kuendgen
authors.forename: T
authors.initials: T
authors.lastname: Gräf
authors.forename: F
authors.initials: F
authors.lastname: Zohren
authors.forename: B
authors.initials: B
authors.lastname: Hildebrandt
authors.forename: A
authors.initials: A
authors.lastname: Hünerlitürkoglu
authors.forename: N
authors.initials: N
authors.lastname: Gattermann
authors.forename: R
authors.initials: R
authors.lastname: Haas
authors.forename: G
authors.initials: G
authors.lastname: Kobbe
mesh_terms: D000208:Acute Disease; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D001374:Azacitidine / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm; D017809:Fatal Outcome; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007279:Injections, Subcutaneous; D007951:Leukemia, Myeloid / Q000175:diagnosis* / Q000188:drug therapy*; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D012074:Remission Induction
chemical_list: D001374:Azacitidine